Abstract
The cytochrome-P450 (CYP) complex aromatase is the rate-limiting step in the production of endogenous estrogen. This synthesis can be controlled with aromatase inhibitor (AI). Different types of AIs are under extensive study for use in the treatment of advanced breast cancer in postmenopausal patients. In view of such significance, the present study explored the pharmacophores of benzofuran derivatives containing pyridine, imidazole and triazole substituents for inhibiting selective aromatase enzyme, CYP19 activity. Implementing classical QSAR (R2=0.858, Q2=0.737, s=0.349, R2 test=0.839) and space modeling (R2=0.908, Δ cost=179.138, rmsd=1.235, R2 test=0.867) approaches, it has been explored that molecular hydrophobicity, presence of suitable ring substituent and hydrogen bond acceptors are the crucial key features of the benzofuran scaffold for imparting CYP19 inhibitory activity. Moreover steric properties of the molecule have influence on the activity.
Keywords: Pharmacophore mapping, QSAR, Space modeling, Benzofuran derivatives, CYP19 aromatase inhibition
Letters in Drug Design & Discovery
Title: Pharmacophore Searching of Benzofuran Derivatives for Selective CYP19 Aromatase Inhibition
Volume: 6 Issue: 1
Author(s): Shuchi Nagar, Md Ataul Islam, Suvadra Das, Arup Mukherjee and Achintya Saha
Affiliation:
Keywords: Pharmacophore mapping, QSAR, Space modeling, Benzofuran derivatives, CYP19 aromatase inhibition
Abstract: The cytochrome-P450 (CYP) complex aromatase is the rate-limiting step in the production of endogenous estrogen. This synthesis can be controlled with aromatase inhibitor (AI). Different types of AIs are under extensive study for use in the treatment of advanced breast cancer in postmenopausal patients. In view of such significance, the present study explored the pharmacophores of benzofuran derivatives containing pyridine, imidazole and triazole substituents for inhibiting selective aromatase enzyme, CYP19 activity. Implementing classical QSAR (R2=0.858, Q2=0.737, s=0.349, R2 test=0.839) and space modeling (R2=0.908, Δ cost=179.138, rmsd=1.235, R2 test=0.867) approaches, it has been explored that molecular hydrophobicity, presence of suitable ring substituent and hydrogen bond acceptors are the crucial key features of the benzofuran scaffold for imparting CYP19 inhibitory activity. Moreover steric properties of the molecule have influence on the activity.
Export Options
About this article
Cite this article as:
Nagar Shuchi, Islam Ataul Md, Das Suvadra, Mukherjee Arup and Saha Achintya, Pharmacophore Searching of Benzofuran Derivatives for Selective CYP19 Aromatase Inhibition, Letters in Drug Design & Discovery 2009; 6 (1) . https://dx.doi.org/10.2174/157018009787158607
DOI https://dx.doi.org/10.2174/157018009787158607 |
Print ISSN 1570-1808 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-628X |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
Recent Advances in Endocrine Metabolic Immune Disorders Drug Targeting: An Editorial Overview
Endocrine, Metabolic & Immune Disorders - Drug Targets Exosomes in Therapy: Engineering, Pharmacokinetics and Future Applications
Current Drug Targets Mitochondria in Cancer Stem Cells: A Target for Therapy
Recent Patents on Endocrine, Metabolic & Immune Drug Discovery Recent Advances in Epitope Design for Immunotherapy of Cancer
Recent Patents on Anti-Cancer Drug Discovery Vitamin D Analogs- Drug Design Based on Proteins Involved in Vitamin D Signal Transduction
Current Drug Targets - Immune, Endocrine & Metabolic Disorders Autologous Mesenchymal Stem Cell Therapy in Progressive Multiple Sclerosis: An Open Label Study
Current Stem Cell Research & Therapy Strategies for Targeting the Multidrug Resistance-1 (MDR1)/P-gp Transporter in Human Malignancies
Current Cancer Drug Targets Editorials (Pharmacogenomics in Primary Care: A Crucial Entry Point for Global Personalized Medicine?)
Current Pharmacogenomics and Personalized Medicine Editorial [Human Methylome Variation and the Rise of Epigenetic Epidemiology]
Current Pharmacogenomics and Personalized Medicine Editorial [Hot Topic: Innate Immune Responses in CNS Neurodegenerative Diseases (Guest Editors: Hans van Noort and Sandra Amor)]
CNS & Neurological Disorders - Drug Targets Cancer/Testis Antigens Trigger Epithelial-Mesenchymal Transition and Genesis of Cancer Stem-Like Cells
Current Pharmaceutical Design The Drug Targeting and Delivery Approach Applied to Pt-Antitumour Complexes. A Coordination Point of View
Current Medicinal Chemistry Plumbagin: A Potential Anti-cancer Compound
Mini-Reviews in Medicinal Chemistry Effect of Salinomycin on Expression Pattern of Genes Associated with Apoptosis in Endometrial Cancer Cell Line
Current Pharmaceutical Biotechnology MicroRNAs as Tools and Effectors for Patient Treatment in Gastrointestinal Carcinogenesis
Current Drug Targets Lectins as Ligands for Directing Nanostructured Systems
Current Drug Delivery Trafficking Potentials of Unconventional T Cell Subsets
Current Medicinal Chemistry - Anti-Inflammatory & Anti-Allergy Agents MUC1 is a Promising Therapeutic Target for Prostate Cancer Therapy
Current Cancer Drug Targets The Epithelial-Mesenchymal Transition and Cancer Stem Cells: Functional and Mechanistic Links
Current Pharmaceutical Design Anticancer Mechanisms of Berberine: A Good Choice for Glioblastoma Multiforme Therapy
Current Medicinal Chemistry